-+ 0.00%
-+ 0.00%
-+ 0.00%
Abbott Initiates VOYAGER CE Clinical Trial Evaluating Investigational Encantor Transcatheter Aortic Valve Implantation Software-Guided Balloon-Expandable System For Treating Symptomatic Severe Aortic Stenosis
Share
Listen to the news
  • Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performance
  • Encantor early feasibility study data will be presented at PCR London Valves 2026

ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis. The first enrollment in the VOYAGER CE study occurred at Macquarie University in Sydney, Australia, led by Stephen Worthley, M.B.B.S, Ph.D.

The prospective, single-arm, pre-market study will enroll up to 300 patients in Europe and Australia with symptomatic severe aortic stenosis caused by severe calcium buildup in the aortic valve. The study will be the basis to seek approval for use in Europe and Australia.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending